Invitae has launched two IVD cancer tests, FusionPlex Dx and LiquidPlex Dx, that have received the CE Mark and are now available in Europe.
Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.
FusionPlex Dx identifies structural variants including fusions in RNA derived from formalin-fixed, paraffin-embedded tumor specimens, and it covers multiple actionable variants in a 41-gene panel. LiquidPlex Dx identifies substitutions and insertion-deletion mutations in cell-free circulating tumor DNA (ctDNA) isolated from plasma derived from liquid biopsy of a cancer patient. It interrogates 29 genes to provide comprehensive genomic profiling for patients with solid malignant neoplasms, according to the company.
Additionally, the panels are intended to be used on Illumina's next-generation sequencing (NGS) platforms for IVD testing.
